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A B S T R A C T
Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its
incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and
treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently
complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding.
Therefore, in this setting, safe and eﬀective methods of VTE prophylaxis and treatment have not been well
deﬁned and hematologists generally refer to guidelines produced for cancer patients that give indications on
anticoagulation in patients with thrombocytopenia. In this review, besides to summarize the incidence and the
available data on prophylaxis and treatment of VTE in HM, we give some advices on how to use antithrombotic
drugs in patients with HM according to platelets count.
1. Introduction
Venous Thromboembolism (VTE) frequently complicates the course
of hematologic malignancies (HM) with a signiﬁcant impact on mor-
bidity and mortality; its incidence is similar to that observed in high-
risk solid tumors (Falanga and Marchetti, 2009; Castelli et al., 2010a).
Pathogenesis of VTE, also in HM, is as usual multifactorial depending
on: a) type and burden of hematological malignancy, b) type of che-
motherapy, c) patients related factors and d) other risk factors such as:
platelet and leukocyte count, presence of infections or central venous
catheter (CVC), interventional procedures (Prandoni et al., 2005).
Moreover, as in solid tumor, neoplastic blood cells and/or leukemic
stem cells may release procoagulant, proinﬂammatory and angiogenic
factors including tissue factor, cancer procoagulant (Gale and Gordon,
2001) and tumor necrosis factor alpha (Grignani and Maiolo, 2000).
Furthermore, the use of high-dose steroids, erythropoietic and myeloid
growth factors contribute to enhance the risk of thrombosis (Wun and
White, 2010; Falanga and Marchetti, 2012; Lee and Levine, 1999). In
addition, chemotherapy may damage the endothelial wall and de-
termine liver function impairment with reduction in circulating phy-
siological anticoagulants (Falanga and Marchetti, 2012; Lee and Levine,
1999). Finally, thrombosis can also be found incidentally during the
diagnostic work up or follow-up for malignancies (den Exter et al.,
2012).
Despite the above evidence, prophylaxis and pharmacologic treat-
ment of VTE in patients with HM is challenging mainly because a severe
thrombocytopenia frequently complicates the course of treatments or is
present since diagnosis. In this particular setting, safe and eﬀective
methods of VTE prophylaxis are challenging and mainly based on ret-
rospective data and expert opinions. The lack of prospective studies or
evidence-based guidelines in the ﬁeld of VTE in HM leads hematologists
to refer to guidelines produced for patients with solid cancers, not or
only partially focused on anticoagulation in patients with thrombocy-
topenia (Carrier et al., 2013). Taking into account this premise, we
performed a systematic review on incidence, prophyaxis and treatment
of VTE in HM, particularly highlighting the “gray zones” in the man-
agement of frail patients, with thrombocytopenia and at high risk of
bleeding
2. Methods
To identify all available studies, a detailed search related to the
occurrence of thrombotic complications during hematological malig-
nancies was performed according to PRISMA (Preferred Reporting
Items for Systematic reviews and Meta-Analyses) guidelines (Moher
et al., 2009). A systematic search was conducted in the electronic da-
tabases (PubMed, Web of Science, Scopus, EMBASE), using the fol-
lowing search terms in all possible combinations: Thrombosis, Venous
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Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis,
Atypical site thrombosis, Mesenteric vein thrombosis, Cerebral sinus
vein thrombosis, Acute leukemia, Acute myeloid leukemia, Acute
lymphoblastic leukemia, Chronic myeloproliferative neoplasms
(MPNs), Polycythemia Vera, Essential Thrombocythemia, Primary
Myeloﬁbrosis, Jak-2 (V617F) gene mutated MPN, Lymphoma, Lym-
phoproliferative disease, Multiple Myeloma,Chemotherapy, Radio-
therapy, Anticoagulant treatment, Low Molecular Weight Heparin, Oral
anticoagulants.
The search strategy was developed with the following language and
publication year restrictions: abstracts written in English, with the
following timeframe limit: from 1st January 1980 to 31st January
2017. Furthermore, the reference lists of all retrieved articles were
manually reviewed. Two independent authors (MN and OA) analyzed
each article and performed the data extraction independently. In case of
disagreement, a third investigator was consulted (GA). Discrepancies
were resolved by consensus. The primary endpoint was to evaluate
characteristics and duration of anticoagulant treatment after VTE in
patients with hematological malignancies; secondary endpoints were
the occurrence and management of recurrent VTE after or during
treatment for a ﬁrst VTE and bleeding.
The main parameters evaluated referred to: indication to antic-
oagulant treatment in patients with hematological malignancies; an-
ticoagulant treatment schedules adopted, hemorrhagic risk evaluation;
eﬃcacy measures of anticoagulant treatment; safety of anticoagulant
treatment. In detail, VTE recurrence and bleeding episodes during an-
ticoagulant treatment were evaluated, if available. The inclusion cri-
teria required a conﬁrmed diagnosis of hematological malignancy and
VTE. Among available data, particular attention was given to frail pa-
tients at high bleeding risk due to severe thrombocytopenia (platelets
count< 30.000/μL). In detail, frail subjects were considered all the
patients with VTE and hematological malignancies under active che-
motherapy treatment and expected or overt severe thrombocytopenia.
Major bleeding was deﬁned as a decrease in hemoglobin of more
than 2.0 g/dL, intracranial or retroperitoneal bleeding requiring sur-
gery or blood transfusion, or any other bleeding necessitating suspen-
sion of anticoagulation and hemostatic approaches. Minor bleeds
comprised all other events. All patient ages were considered.
2.1. Data extraction and quality assessment
According to the pre-speciﬁed criteria, all studies related to venous
thrombosis in the course of HM were included. Single case-reports,
abstract from conferences and animal studies were excluded. To be
included in the analysis, a study had to provide data on venous
thrombosis (clinically suspected and instrumentally diagnosed), their
management, any underlying hematological malignancies and treat-
ment. Because of the wide variability in the outcomes considered,
neither formal study quality assessment nor meta-analytic evaluation
were performed.
3. Results
The search provided 556 results, of which 480 were excluded be-
cause they were single case reports or judged oﬀ the topic after scan-
ning the title and the abstract (articles related to biological and la-
boratory aspects of VTE in cancer, N= 75; articles and reviews not
referring to hematological malignancies, N= 297; papers reporting
VTE secondary to surgical procedures or medical illness other than
blood cancer, N= 108). In addition, seven studies were excluded after
evaluation of the full-length paper (Fig. 1). Only three studies speciﬁ-
cally evaluated the safety of LMWH in frail thrombocytopenic patients
with hematological malignancies (Khanal et al., 2016; Lim and Enjeti,
2016; Imberti et al., 2004). However, these studies do not reach a
statistical power to be considered useful.
Before the publication of the CATCH study (Lee et al., 2015a), we
have identiﬁed only 5 randomized clinical studies dealing with antic-
oagulant treatment of VTE in cancer patients (Meyer et al., 2002; Hull
et al., 2006; Lee et al., 2003; Deitcher et al., 2006; Romera et al., 2009).
Only 2 of these studies (Meyer et al., 2002; Hull et al., 2006) accrued
patients with HM who are generically reported as hematologic cancer,
without any detail on the type and characteristics of HM. The same is
reported in the CATCH study, the last of these studies, where 94/900
(10.4%) patients had an unspeciﬁed hematologic tumor (Lee et al.,
2015a). Therefore, we were unable to adopt these studies for the pur-
pose of our review.
3.1. Acute leukemia
3.1.1. Reported incidences of VTE (Table 1)
VTE incidence in AL ranges from about 2% up to 12% (Ziegler et al.,
2005; Ku et al., 2009; De Stefano et al., 2005; Melillo et al., 2007; Vu
et al., 2015; Rickles et al., 2007). Ku et al. (2009) have observed a 2-
year VTE cumulative incidence of 5.2% in AML and 4.5% in ALL, in a
cohort study on 7876 patients with acute leukemia, mainly during the
ﬁrst month of diagnosis: age, comorbidities and CVC were reported as
the most frequent associated risk factors for VTE.
De Stefano et al. (2005) evaluated the risk of VTE in a cohort of 379
adult patients with a newly diagnosed AL; overall, VTE episodes oc-
curred in 19 (5%) patients and in 13 cases of entire population (3.4%),
it was the presenting manifestation. In particular, VTE at diagnosis was
observed in 1.4% of ALL, 9.6% of APL and 3.2% of other AML. More-
over, patients treated with L-asparaginase had a 4.9 fold increased risk
of thrombosis (95%CI: 1.5–16). Death rate due to thrombosis was 0.8%
and, diﬀerently from AML, in ALL the occurrence of VTE increased of
40% the risk of dying within 1 year.
Estimated incidence of VTE in children with ALL, derived from
prospective studies, range from 3% to 36.7% (Shapiro et al., 1993;
Mitchell et al., 1994; Athale and Chan, 2003). A meta-analysis of 17
studies showed a 5.2%, rate of thrombosis in pediatric patients with
ALL mainly during induction therapy with L-asparaginase (Caruso
et al., 2006). A similar trend (incidence rate of 5.9%) was observed in
adults with ALL from 13 published prospective studies including 323
patients (Caruso et al., 2007).
A study performed by the GIMEMA (Gruppo Italiano Malattie
Ematologiche dell’Adulto) on 124 patients with acute promyelocytic
leukemia (APL) treated with ATRA and Idarubicin showed an incidence
rate of VTE of 8.8% (Breccia et al., 2007).
Vu et al. (2015) recently published a retrospective study on 1295
patients with AL reporting a prevalence of VTE of 10.7%. Most VTEs
occurred within 3 months from diagnosis; however, most of them were
upper extremity CVC related deep vein thrombosis and occurred mainly
in ALL (Table 1).
3.1.2. Treatment options
Most of the reported VTE in AL are CVC-related (Oliver et al., 2015)
and their anticoagulant treatment with Low Molecular Weight Heparin
(LMWH) has been shown safe and eﬀective when retrospectively
compared with no treatment (Frere et al., 2014; van Doormaal et al.,
2011).
Recently, in a multicenter study on 1461 patients with AL, our
group has demonstrated the occurrence of non-CVC related VTE also in
patients with severe thrombocytopenia (PLT<30.000/μL). Treatment
with LMWH, at a full dose for one month and adjusted regimens for the
following 3 months resulted safe and eﬀective in the reported cohort of
patients with AL (Napolitano et al., 2016).
Treatment recommendations of VTE in children with ALL are ex-
trapolated from adults. The American College of Chest Physicians
(ACCP) Evidence based Clinical Practice Guidelines for children (9th
edition) deﬁnes optimal strategies for the management of thrombosis in
children, with and without cancer (Monagle et al., 2012). LMWH re-
mains the most suitable treatment option also in the setting of ALL due
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to frequent periods of thrombocytopenia and intermittent temporary
cessation for lumbar punctures. However, it is suggested that platelet
count should be maintained above 50,000/μL in patients on therapeutic
anticoagulation, while consideration should be given to temporary
cessation or dosage reduction of anti-coagulation when there is an in-
ability to maintain platelet count at that level (Monagle et al., 2012;
Sutor et al., 2004).
In children, to avoid late organ damages, thrombolysis is frequently
taken into account as a safe treatment option; even though, a survey of
pediatric hematologist and oncologists from USA, has shown no con-
sensus on indications, dose, mode of delivery, or duration of throm-
bolysis therapy in young patients with ALL (Yee et al., 2009). Recently,
Ross et al. (2016) have retrospectively evaluated anticoagulant treat-
ment administered to 122 patients with malignancies, 26 of these pa-
tients (21%) were treated with direct oral anticoagulants (DOACs). This
study showed VTE recurrences in 7.7% of patients receiving DOACs and
7.9% of patients treated with LMWH (P=n.s.), without signiﬁcant
diﬀerences in the incidence of major bleeding complications.
Therefore, from this small study DOACs seem equivalent to LMWH
for safety and eﬃcacy. However, the low number of hematological
malignancies included in this study, does not allow extrapolating these
results in all AL.
Antithrombin (AT) replacement is still a debated issue in the man-
agement of thrombosis after asparaginase in patients with ALL. Fresh
frozen plasma transfusion resulted ineﬀective in raising antithrombin
levels (Abbott et al., 2009), while PARKAA study (Mitchell et al., 2003)
showed a trend towards eﬃcacy and safety of AT concentrates.
So far, there are no prospective studies addressing the issue of VTE
prophylaxis in patients with AL; some data can be obtained from studies
on CVC-related thrombosis prophylaxis.
Lee et al. (2015b) have recently performed a survey to deﬁne pro-
phylactic approaches of VTE in AL, they found that approximately in
half cases only mechanical prophylaxis (13%) or no treatments (36%)
at all were administered. When pharmacological prophylaxis was
adopted, sub-cutaneous heparin, alone or in combination with me-
chanical prophylaxis (sequential compression device or stockings), was
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Fig. 1. PRISMA Flow Diagram.
Table 1
Incidence of vte in acute leukemias.
Reference # pts Type of study # VTE %
a) Acute Myeloid Leukemia
21 485 Retrospective 8 1.6
22 5057 Registry 183 3.6
23 279 Observational Cohort 12 5.2
24 51 Prospective 5 8.9
25 923 Retrospective 78 8.5
b) Acute Lymphoblastic leukemia
21 185 Retrospective 4 2.1
22 2482 Registry 113 4.5
23 69 Observational Cohort 7 10.6
24 42 Prospective 2 4.5
25 299 Retrospective 53 17.7
27 15 Prospective 1 6.6
30 1752 Meta-analisys in pediatric patients 91 5.2
31 323 Meta-analisys in adult patients 19 5.8
c) Acute Promyelocitic Leukemia
21 49 Retrospective 3 6.1
22 337 Registry 12 3.6
23 31 Observational Cohort 5 8.4
24 10 Prospective 4 28.5
25 73 Retrospective 8 11
32 124 Prospective 13 10.5
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the treatment of choice, either during induction or maintenance che-
motherapy.
Couban et al. (2005) performed a placebo controlled study on
prophylaxis with low dose warfarin to prevent CVC related thrombosis,
including approximately 24% patients with AL. Prophylaxis was dis-
continued for platelet count< 20,000/μL or if there were many
treatment interruptions. Treatment with low dose warfarin was well
tolerated despite the incidence of CVC related thrombosis was not in-
ﬂuenced by prophylaxis and treatment.
Some studies, including patients with AL and CVC-related throm-
bosis, have conﬁrmed these results and the safety of prophylactic low
dose warfarin (Cortelezzi et al., 2005; Del Principe et al., 2013; Niers
et al., 2007).
However, a randomized prospective study conducted by Verso et al.
(2005) in 385 cancer patients of whom 33(8.5%) with HM requiring
CVC, did not demonstrate a utility of prophylactic therapy in reducing
CVC thrombosis in the entire population. No data are available for the
subgroup of patients with HM.
Elhasid et al. (2001) reported the safe administration of LMWH
(enoxaparin, mean dose, 0.84mg/kg once daily), in comparison with
historical controls not treated with prophylactic LMWH, in preventing
thrombosis in 41 patients with ALL. Enoxaparin was administered
subcutaneously starting at the ﬁrst dose of L-asparaginase until 1 week
after the last dose. Thrombosis was not reported during 76 courses of
administered treatment. In the historical control group of 50 ALL
children, two had thromboembolisms during L-asparaginase treatment.
Enoxaparin prophylaxis combined to antithrombin infusion resulted
eﬀective in preventing symptomatic VTE in 41 children with ALL, when
compared to antithrombin alone (n=71), results from the reported
prospective cohort study (Meister et al., 2008) however have not been
yet conﬁrmed in a randomized trial
3.2. Chronic myeloproliferative neoplasms
3.2.1. Reported incidence of VTE (Table 2)
In the largest available epidemiological study on Polycythemia Vera
(PV) by the European Collaboration on Low-dose Aspirin in
Polycythemia Vera (ECLAP), pulmonary embolism determined 8% of
all deaths with a cumulative rate of non-fatal thrombosis of 3.8 events
per 100 persons per year (Marchioli et al., 2005). Incidence of VTE
prior and after trial entry are reported in Table 2, among the 1638
patients of this study, 518 were randomized to receive or not low-dose
of aspirin (Landolﬁ et al., 2004).
The incidence of VTE in Essential Thrombocythemia (ET) has been
reported in two prospective studies, as 1% patient-years (Harrison
et al., 2005; Gisslinger et al., 2013). In primary myeloﬁbrosis, non-fatal
VTE was reported in 0.76% of patients per year (Barbui et al., 2010). At
diagnosis, the prevalence of clinically relevant thrombosis has been
reported to vary from 11 to 39% in PV and from 8 to 29% in ET
(Papadakis et al., 2010; Elliot and Teﬀeri, 2005; Teﬀeri and Barbui,
2015).
Chronic myeloproliferative neoplasms (MPN) are characterized by
the occurrence of VTE in atypical sites, in particular splanchnic vein
thrombosis (SVT) and Budd-Chiari syndrome. Reported prevalence of
SVT in MPN ranges from 1% (Gangat et al., 2006) to 23% (De Stefano
et al., 2007) and higher rates of SVT are reported in female sex. Clinical
risk predictors for thrombosis in MPN do not distinguish between ar-
terial and venous events, (Carobbio et al., 2011) and include: age, a
previous history of thrombosis and increased leucocyte blood count
(Barbui et al., 2009). Carobbio et al. (2011) performed a multivariate
analysis of 891 patients with ET for variables including age>60 years,
history of thrombosis, cardiovascular risk factors, JAK-2 mutational
status, leukocyte count> 11,000/μL and platelets count> 1,000,000/
μL, they observed that only male gender was signiﬁcantly associated
with a higher risk of VTE (HR 1.99;95% CI 1.03–3.83).
Campbell et al. (2005) studied 806 patients with ET showing a
higher risk for thromboembolic events in patients with JAK-2 V617F
mutated ET compared with JAK-2 V617F wild type ET.
A systematic review has shown that patients with JAK-2 (V617F)
mutation have a 2-fold risk of developing thrombosis, both of venous
and arterial vessels (OR 2.49 and 1.77, respectively), (Lussana et al.,
2009).
In ET, the risk of thrombosis has been reported as increased by the
concomitance of JAK-2 V617F mutation and inherited thrombophilia
(De Stefano et al., 2009).
3.2.2. Treatment options
Current guidelines suggest managing patients with VTE in MPN like
subjects with persistent risk factors (Kearon et al., 2016). In the largest
available study on VTE recurrences after a ﬁrst episode in MPN, long-
term anticoagulation determined a 63% reduction in the risk of recur-
rence without a signiﬁcant increase in the incidence of major bleeding,
as compared with patients without antithrombotic treatment (1.2%
patient-years), (De Stefano et al., 2008).
Long-term treatment with low dose aspirin determined a signiﬁcant
lower rate of relapses, compared to VKA (Vitamin K Antagonists) (ASA,
HR 0.42; 95%CI: 0.22–0.77; VKA, HR 0.32; 95%CI: 0.15–0.64), (De
Stefano et al., 2008). Moreover long-term oral anticoagulant treatment
for SVT is recommended.
In a survey including 42 patients with MPN, anticoagulant therapy
showed a reduction in the risk of portal vein thrombosis extension and
recurrence without signiﬁcantly aﬀecting incidence and severity of
bleeding complications (Condat et al., 2001).
In PV, 2 randomized clinical trials showed a signiﬁcant reduction of
cardiovascular events by cytoreductive treatment (for reduction of he-
matocrit) and low dose ASA (Landolﬁ et al., 2004; Marchioli et al.,
2013). Prophylaxis with low doses of aspirin (ASA, 100mg/day) has
been shown to signiﬁcantly reduce the risk of thrombotic events in-
cluding major venous thromboembolism (RR=0.40; 95% CI:
0.18–0.91; P= 0.0277), (Campbell et al., 2005). The clinical eﬃcacy of
Table 2
Incidence of VTE in Myeloprolipherative Neoplasms (MPN).
Ref. MPN # of Patients Type of study # VTE (%) Prior trial entry # VTE (%) After trial entry Risk Factors for VTE
51 PV 1638 Prospective 225 (13.7) 88 (5.4) Age ≥65 years Prior thrombosis
53 ET 404 HU +ASA OLRT 29 (7.1) 14 (3.5) NR
405 ANA +ASA 20 (4.9) 3 (0.7)
54 ET 122 ANA RCT NR 2 NR
131 HU 6
55 PMF 707 Prospective 32 (4.5) 31 (4.4) Age>60 years, JAK2+, WBC ≥15.000/μL
63 ET 414 JAK2 + Prospective 11 (2.7) 12 (2.9) Presence of JAK2 V617F mutation
362 JAK2wt negative 2 (0.55) 4 (1.1)
64 ET 1173 JAK2 + Meta-analysis 127 (10.8) Presence of JAK2 V617F mutation
953 JAK2wt 41 (4.3)
Legend: Ref: reference number; PV: Policithemia Vera; PMF: Primary myeloﬁbrosis; ET: Essential Thrombocitemia; HU: Hydroxiurea; ASA: Aspirin; ANA: Anagrelide; DBPCT: Double
Blind Prospective Controlled trial RCT: Randomized controlled trial; OLRT=open label randomized trial; NR=not reported; wt=wild type.
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prophylaxis with ASA in patients with essential Thrombocythemia is,
on the contrary, not based on randomized clinical trials. Moreover, it
must be taken into account the potential higher bleeding risk of patients
with a platelet count> 1,500,000/μL (Barbui et al., 2011; Barbui et al.,
2013).
Alvarez-Larrán et al. (2010) performed a retrospective study on 300
patients with low-risk ET showing that thrombosis was unaﬀected by
ASA. A subgroup analysis showed that JAK-2 mutated subjects with ET
suﬀered more venous thrombosis than un-mutated subjects.
Low-dose ASA is currently recommended in essential thrombo-
cythemia patients with microvascular symptoms like transient neuro-
logical attacks (Barbui, 2011).
An observational study in ET, combining ASA with chemotherapy
reported a signiﬁcant reduction of vascular events, including venous
thrombosis, only in patients older than 60 years, when compared to
chemotherapy alone (29.2 vs. 8.6 events of VTE/1000 patients year,
P= 0.02) (Alvarez-Larrán et al., 2013). This signiﬁcant reduction in
VTE was associated to a signiﬁcant increase in bleeding complications
(14.4 vs. 1.4 hemorrhagic events/1000 patients-years, P= 0.006).
Combined treatment with ASA and anagrelide for ET resulted in a
signiﬁcant reduction of VTE when compared with ASA plus hydoxyurea
(HR 0, 27; 95% CI: 0.11–0.71; P= 0.006), (Harrison et al., 2005) even
though this reduction in VTE was associated with a higher bleeding
risk. On the contrary, the ANAHYDRET trial (Gisslinger et al., 2013)
showed no signiﬁcant diﬀerences between hydroxyurea and anagrelide
in the occurrence of VTE and bleeding events.
Data from the RESPONSE trial, where the new JAK-2 inhibitor
ruxolitinib was administered to patients with PV unresponsive or not
tolerant to hydroxyurea, showed a lower rate of VTE in the ruxolitinib
group: with thromboembolic event rate per 100 patient-years of 1.8 in
patients randomized to ruxolitinib vs. 8.2 in those treated with best
available therapy (Verstovsek et al., 2016).
3.3. Hodgkin’s and non-Hodgkin’s lymphoma
3.3.1. Reported incidence of VTE (Table 3)
Two studies have prospectively evaluated VTE incidence in patients
with lymphoma (Ottinger et al., 1995; Khorana et al., 2005). In the ﬁrst
study, conducted in 593 patients with high-grade non-Hodgkin’s lym-
phoma, a 6.6% incidence rate of VTE was reported (Ottinger et al.,
1995). The second study, performed in ambulatory patients found a
VTE rate of 8.16% in Hodgkin’s disease and 1.5% in non- Hodgkin’s
lymphoma (Khorana et al., 2005). Mohren and colleagues (Mohren
et al., 2005), in a single center analysis found an overall thromboem-
bolic event incidence of 7.7% in 1038 treated lymphoma patients with a
statistically signiﬁcantly higher incidence in high grade than in low-
grade lymphoma. These ﬁndings, along with the fact that most patients
had their thrombotic event during or after chemotherapy, suggests that
histotype and chemotherapy may have a key role in triggering throm-
botic events in patients with lymphoproliferative disease.
A registry-based analysis including 16,755 cases of non-Hodgkin’s
lymphoma, found a 4.0% 2-year cumulative incidence of acute VTE that
was also a strong predictor of decreased survival (Mahajan et al., 2014).
As regards to the pathogenesis of VTE in lymphomas, it has been ob-
served that, beside the classical conditions (immobility, infections, age,
CVC, chemotherapy, use of hematopoietic growth factors (Castelli et al.,
2010b), a mediastinal mass in pediatric patients could be an additional
risk factor (Athale et al., 2008).
A meta-analysis (Caruso et al., 2010) regarding 18,018 lymphoma
patients belonging to 29 independent cohorts revealed a global IR
(Incidence Risk) of thrombosis in lymphoma patients higher than 6%
with most of the events occurring during the treatment of the disease.
Because in the majority of the studies, patients were followed-up from
diagnosis to an extent of 1–3 years (treatment period being usually of
6–12 months), this pooled IR has to be considered particularly high.
However, in this meta-analysis, 95% of thrombosis occurred during
treatment and therefore, it was impossible to distinguish between the
thrombogenic eﬀects of lymphoma itself or of its treatment. Never-
theless, the high rate of thrombotic events observed in lymphoma pa-
tients stands as a problem in their clinical management, irrespective of
the cause, either lymphoma or the treatments. Moreover, the subgroup
analyses revealed a diﬀerent pooled Incidence Risks (IRs) of thrombotic
events in diﬀerent subtypes of lymphoma (Caruso et al., 2010). In
particular, compared with all types of NHL, HL patients had a statisti-
cally lower incidence of thrombosis and high grade NHL exceeded low
grade NHL in the rate of thrombotic events. An increased incidence of
VTE was also observed in lymphomas with advanced stage.
Ottinger et al. (1995) investigated the risk factors for VTE in dif-
ferent subtypes of high grade NHL, the only independent risk factor for
VTE in this population was the presence of mediastinal clear cell sub-
type, and the bulky mediastinal mass responsible of veins compression
was the dominant cause of thrombosis. In addition, also the advanced
stage was an independent risk factor for VTE. Compression of veins by
local growth of lymphoma was identiﬁed as the main cause of VTE in
50% of cases, including all 12 patients who developed thrombosis be-
fore treatment and one third of patients with thrombosis during che-
motherapy (Ottinger et al., 1995).
A large population-based case-control study performed in cancer
patients, showed that patients with lymphoma had the greatest risk of
venous thrombosis (odds ratio [OR] 10.2, 95% CI, 1.4–76.9), followed
by lung and gastrointestinal cancer patients (Blom et al., 2005).
Another study on more than 65,000 neutropenic cancer patients
reporting more than 5000 thrombotic events revealed that patients with
lymphoma and leukemia accounted for one third of venous and nearly
one half of arterial events (Khorana et al., 2006). Recently, in a vali-
dated predictive model for chemotherapy associated thrombosis, lym-
phoma resulted in the high-risk group for developing thrombosis, along
with lung, gynecologic, and genitourinary cancers with an independent
OR for Thrombosis of 1.5 (0.9–2,7), (Khorana et al., 2008). These in-
vestigators indicated the following 5 variables responsible for an in-
creased incidence of VTE: site of cancer, platelet count 350,000/μL or
greater, hemoglobin less than 10 g/dL and/or use of erythropoiesis-
stimulating agents, leukocyte count greater than 11,000/μL, and body
mass index 35 kg/m2 or greater.
Because data regarding the type of therapy across studies, were
heterogeneous, and not all authors reported name and dosage of the
drugs used, it was not possible to evaluate the role of the diﬀerent
treatment interventions in the risk of VTE.
As for Central Nervous System Lymphoma (CNSL), a study including
diﬀerent types of NHL revealed thrombotic events in 12 patients with
CNSL with IR of 8.3% a rate similar to that found in other high grade
NHLs (Mohren et al., 2005). In a second study, including only CNSL the
Table 3
Incidence Of VTE In Lymphomas.
Reference # pts Type of study # VTE %
a) Non Hodgkin Lymphoma
76 593 Prospective clinical trial 34 6.6
77 267 Observational 4 1.5
78 348 High Grade Retrospective 37 10.6
485 Indolent 28 5.77
79 16,755 Registry 603 3.6% at 1 ys
670 4.0% at 2 ys
81 75 Pediatric Retrospective 9 12
82 15,410 Meta-analysis 997 6.5
b) Hodgkin Lymphoma
77 49 Observational 4 8.16
78 193 Retrospective 14 7.25
82 2505 Meta-analysis 118 4.7
c) CNS Lymphoma
78 12 Retrospective 1 8.33
82 54 Meta-analysis 26 48.1
86 42 Retrospective 25 59.5
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incidence rate of VTE was extremely high reaching 59% (Goldschmidt
et al., 2003). This high incidence was also conﬁrmed in the meta-ana-
lysis by Caruso et al. where among 54 CNS lymphoma, 26 (48.1%) had
a VTE.
3.3.2. Treatment options
As in other hematological malignancies, the use of anticoagulant
drugs may contribute to an increased risk of bleeding. Therefore, taking
into account this increased bleeding risk, anticoagulation, as throm-
boprophylaxis, is rarely prescribed in patients with lymphoma diﬀer-
ently from treatment of VTE. Considering that thrombosis is a frequent
event in lymphoma patients and it is associated with several detri-
mental eﬀects, the possibility of stratifying the risk would allow an
appropriate use of anticoagulant treatment in patients at high risk ac-
cording to clinical guidelines. The presence of high grade Lymphoma,
advanced stage of disease, mediastinal clear cell subtype, vein com-
pression, congenital thrombophilia and use of CVCs could represent risk
factors for thrombosis occurrence and should therefore be evaluated for
antithrombotic prophylaxis with LMWH.
As proposed by ASCO guidelines, in cancer patients, thrombopro-
phylaxis may be suggested in all hospitalized lymphoma patients;
whereas in outclinic patients, prophylactic anticoagulation is re-
commended only for those receiving thalidomide or lenalidomide,
providing that in both situations a platelet count is> 50,000/μL
(Lyman et al., 2007).
3.4. Monoclonal gammopathy of undetermined signiﬁcance (MGUS) and
multiple myeloma (MM)
3.4.1. Reported incidence of VTE (Table 4)
Compared with the general population, patients with MGUS and
MM have a higher risk of deep vein thrombosis (DVT) as clearly de-
monstrated by Kristinsson and coworkers in a study published in 2008
(Kristinsson et al., 2008). In this study, the authors have compared the
incidence of DVT in 2374 MGUS and 6192 MM to that observed in
4,187,631 patients admitted during a period of 16 years (October 1,
1980–September 30, 1996) in the US Veterans Aﬀairs hospitals. The
results of this study demonstrated that compared with the entire study
population, the relative risk (RR) of DVT after a diagnosis of MGUS or
MM was 3.3 (95% CI 2.3–4.7) and 9.2 (95% CI 7.9–10.8), respectively.
The most prominent excess risk of DVT was found during the ﬁrst year
after diagnosis of MGUS (RR=8.4; 95% CI 5.7–12.2) and MM
(RR=11.6; 95% CI, 9, 2–14.5).
The introduction of immunomodulatory (IMiDs) drugs in the
standard treatment of MM, especially when combined with dex-
amethasone or other glucocorticoids and/or cytotoxic chemotherapy,
has further increased the risk of DVT among MM patients (Palumbo
et al., 2008; Musallam et al., 2009). Two meta-analysis have conﬁrmed
these data (El Accaoui et al., 2007; Carrier et al., 2011).
In a prospective analysis of 310 individuals (Sallah et al., 2004) with
MGUS the incidence of VTE was 6.1%, thus conﬁrming the rate of 7.5%
observed in a retrospective study on 174 patients (Srkalovic et al.,
2004). More recently, a retrospective cohort study conducted in Italy on
1491 MGUS patients found that the VTE risk was higher when the
serum monoclonal protein concentration exceeded 16 g/L (Za et al.,
2013). However, in a study analyzing the Swedish Cancer Registry
(Kristinsson et al., 2010) to identify all MM patients diagnosed between
1958 and 2006 and a nationwide MGUS cohort, diagnosed during the
same period,the risk of thrombosis did not vary by M-protein con-
centration (> 10 g/L or< 10 g/L). Nevertheless, the risk of venous and
arterial thrombosis was increased at 1, 5 and 10 years after diagnosis in
both MGUS and MM patients (Table 4). Moreover, only IgG and IgA
(but not IgM) MGUS had an increased risk for venous and arterial
thrombosis. The study population of this study was represented by
18,627 MM and 5326 MGUS who were compared to 70,991 and 20,161
matched controls respectively (Kristinsson et al., 2010).
3.4.2. Treatment options for multiple myeloma
Panel consensus from the International Myeloma Work Group
(IMWG) has agreed that the choice of thromboprophylaxis depends on
the individual risk of VTE, as determined by patient and treatment
related factors, such as obesity, prior VTE, central venous catheter or
pacemaker, immobilization, recent surgery, comorbidities, blood clot-
ting disorders, use of erythropoietin stimulating agents, and myeloma
therapy (IMiDs, high dose dexamethasone or doxorubicin) (Palumbo
et al., 2008).
ASA is recommended for patients with one or no risk factors, and
LMWH for those with more than one risk factor (Palumbo et al., 2008).
However, the optimal approach to thromboprophylaxis has not yet
been established and published data show conﬂicting results. Therefore,
further randomized controlled trials are needed to address this im-
portant clinical need (Carrier et al., 2011; Al-Ani et al., 2016).
3.5. Amyloidosis AL
3.5.1. Reported incidence of VTE
Amyloidosis AL may aﬀect hemostasis with severe thrombotic (Falk
et al., 1997; Freeman et al., 2012; Halligan et al., 2006) and bleeding
complications (Gamba et al., 2000; Yood et al., 1983). Nephrotic syn-
drome, a common presentation of AL, may contribute to the risk of VTE,
in this population, because it is associated with hypercoagulability
(Christiansen et al., 2014; Kerlin et al., 2012). Other potential con-
tributors to VTE risk in AL are, as in MM, immunomodulatory agents
(IMiDs) (Bennett et al., 2006). Recently Bever et al. (Bever et al., 2016)
reported that 65/629 patients (7%) with AL, presenting to a single re-
ferral center, experienced at least one venous thromboembolic event
and in 80% of these 65 patients, the events manifested within one year
prior to or following diagnosis. In this setting, serum albumin< 3 g/dl
was associated with increased risk of VTE, with a hazard ratio of 4.30
(CI 1.60–11.55; P=0.0038). Severe bleeding complications were ob-
served in 5 out of 57 patients with venous thromboembolism under-
going anticoagulation with LMWH. Therefore, anticoagulant treatment
may be associated with signiﬁcant hemorrhagic complications in
amyloidosis AL. A better understanding of the causes of the patients
who are at risk of VTE may help clinicians in the management of these
patients and low levels (< 3 gr/dl) of serum albumin is strongly cor-
related with an increased risk of VTE in patients with Amyloidosis AL.
3.5.2. Treatment options for amyloidosis
Given the high rate of bleeding complications in these patients,
Table 4
Incidence Of VTE In Paraproteinemias.
Reference # pts Type of study # VTE %VTE
a) MGUS
88 2374 Observational 31 1.3
93 310 Prospective 19 6.1
94 174 Observational 13 7.4
95 1491 Retrospective 49 before diagnosis 3.3
33 after diagnosis 2.2
82 Total 5.5
96 5326 Registry 85 at 1 yr 1.6
212 at 5 yr 4.0
317 at 10 yr 6.0
b) Multiple Myeloma
88 6192 Observational 151 2.4
94 404 Prospective 40 9.9
96 18,627 Registry 404 at 1 yr 2.1
722 at 5 yr 3.9
832 at 10 yr 4.5
c) Amyloidosis AL
100 2132 Registry 40 0.1
106 929 Retrospective 65 7
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prophylactic anticoagulation cannot be recommended without pro-
spective randomized trials determining the risk/beneﬁt ratio of pro-
phylactic anticoagulation.
3.6. Waldenström macroglobulinemia (MW) and lymphoplasmocitic
lymphoma (LPL)
3.6.1. Reported incidence of VTE
Reports on the risk of VTE in patients with WM or LPL are limited.
Hultcrantz, et al. (Hultcrantz et al., 2014) assessed the risk of venous
and arterial thrombosis in WM/LPL patients in a large population-based
cohort study conducted in Sweden. In this study, comparing the in-
cidence of thromboembolism in 2190 patients with WM/LPL and 8086
matched controls, WM/LPL had a signiﬁcantly increased risk of venous
thrombosis and the highest risk was observed during the ﬁrst year
following diagnosis (HR=4.0, 95% CI 2.5–6.4). The risk persisted
signiﬁcantly elevated at 5 (HR=2.3, 95% CI 1.7–3.0) and 10 years
following diagnosis (HR=2.0, 95% CI 1.6–2.5). No increased risk of
arterial thrombosis was observed at any time during follow-up time.
The results are consistent with previous ﬁndings showing that patients
with IgM MGUS do not have an increased risk of arterial thrombosis (Za
et al., 2013). The reason for the elevated risk of venous thrombosis is as
usual multifactorial and hyperviscosity associated with a high IgM
paraprotein may play an important role (Stone and Bogen, 2012;
Kwaan, 2013). The potential role of thromboprophylaxis in WM/LPL,
especially during the ﬁrst year after diagnosis and in patients treated
with thrombogenic agents needs to be assessed to further improve
outcome in WM/LPL patients.
3.6.2. Treatment options for WM and LPL
It has been suggested that IgM paraprotein can impair platelet ag-
gregation and thereby prevent arterial thromboembolism (Kwaan,
2013). The ﬁndings of increased risk of VTE indicate that certain WM/
LPL patients may beneﬁt from thromboprophylaxis with LMWH.
4. Discussion
Prophylaxis and therapy of VTE remains a challenging issue in pa-
tients with HM due to the high incidence of thrombocytopenia observed
in this setting. Available data on VTE in HM are often diﬃcult to
compare for several reasons: a) the diﬀerent type of HM; b) the diﬀerent
stage of the diseases; c) the diﬀerent antineoplastic chemotherapies; d)
the small number of patient enrolled in the studies.
Patients with HM may have profound abnormalities of the hemo-
static system, predisposing them to an increased risk of hemorrhagic
complications. Therefore, because of the lack of speciﬁc guidelines for
the prophylaxis and management of VTE in HM, hematologists apply
the clinical experience derived from guidelines in cancer patients.
The unique contribution of this review consists in the fact that for
the ﬁrst time VTE diagnosis and management has been detailed for each
subtype of HM.
The preferred option for prophylaxis and treatment of VTE in pa-
tients with cancer is LMWH because it is more eﬀective than warfarin
for the secondary prevention of VTE in cancer patients (Hull et al.,
2006). Data related to the eﬃcacy and safety of anticoagulation with
DOACs are limited to few patients, and no reliable indications may be
given. Therefore, the administration of DOACs is currently not sup-
ported by well-designed clinical trials.
From our results it is evident that randomized controlled trials
(RCT) dedicated to the incidence, prophylaxis and treatment of VTE in
HM are lacking with the exception of studies conducted in PV and ET
(Table 2). These RCT speciﬁcally designed for PV and ET have clearly
indicated that the introduction, since the diagnosis, of aspirin in the
treatment of these patients clearly prevent cardiovascular events.
Moreover, from these studies it was evident the role of JAK2 mutation
and leukocytosis as risk factors for VTE. As for acute leukemias, the
presence of severe thrombocytopenia during induction and consolida-
tion therapies has greatly limited the use of antithrombotic prophylaxis
and treatments in these patients. Therefore, we urgently need RCT to
identify safe and eﬃcient antithrombotic drugs that may be utilized in
patients with acute leukemias during induction and consolidation
therapies. These studies should also contribute to verify which is the
lower platelet level for safe and eﬃcient administration of these drugs.
Unfortunately, the RCT conducted in cancer patients do not provide
useful clinical information about the HM enrolled in these studies.
Therefore, their results did not contribute to the solution of this pro-
blem and the few studies available in acute leukemias did not have
suﬃcient statistical power to answer these important questions.
Several studies with low statistical power, suggest that antith-
rombotic drugs are needed to prevent VTE in MM patients treated with
IMiDs even though none of these studies has clearly indicated which
should be the preferred drug. Therefore, investigators use aspirin of
LMWH as prophylaxis based on what has been suggested by a panel
consensus from the IMWG (Palumbo et al., 2008). However, also in this
setting we need well-designed randomized clinical trials to have useful
guidelines based on objective results rather than on expert opinions.
Awaiting these studies, we continue to use what has been proposed by
the panel consensus of the IMWG (Palumbo et al., 2008). Because of
their similarity with solid tumors, prophylaxis and treatment of VTE in
Hodgkin and non-Hodgkin lymphomas may follow the guidelines pro-
posed for cancer patients (Lyman et al., 2007).
Table 5 summarize our personal suggestions for the prophylaxis and
treatment of VTE in HM. We suggest discontinuation of antithrombotic
drugs for platelets count ≤50.000/μL in case of aspirin and with pla-
telets count ≤20,000/μL in case of LMWH. Full dose of aspirin and
LMWH should be given with platelets count> 50,000/μL. In case of
platelets count between 20,000 and 50,000/μL, we suggest a 50% dose
reduction of LMWH.
5. Conclusion
VTE is a frequent complication in patients with HM. Observational
studies and the few randomized controlled trials, mainly conducted in
cancer patients, over the last two decades have contributed to our
better understanding of the pathogenesis of VTE and its management.
Future studies in this setting should provide a solution to the following
questions:
1) Which is the best antithrombotic prophylaxis and treatment for VTE
in hospitalized and ambulatory patients with HM?
2) Which is the best antithrombotic prophylaxis and treatments for
VTE in patients at standard or elevated bleeding risk?
3) Which may be the role of DOACs in the prophylaxis and treatment of
VTE in HM?
To answer these questions, randomized controlled trials are ur-
gently needed in order to compare the eﬃcacy and safety of the various
antithrombotic agents in the diﬀerent HM. These studies will provide
guidelines on how to approach VTE complications in the diﬀerent HM.
So far, these studies have been well conducted only in PV and ET where
the routine use of ASA prophylaxis has deeply contributed to the pre-
vention of major and minor cardiovascular events.
Conﬂict of interest statement
None.
Author’s contributions
GA and SS conceived the study, AO and MN performed literature
search, data analysis and wrote the article. GA and SS critically revised
the paper; all authors gave their ﬁnal approval to the submitted version.
O. Annibali et al. Critical Reviews in Oncology / Hematology 124 (2018) 41–50
47
References
Abbott, L.S., Deevska, M., Fernandez, C.V., Dix, D., Price, V.E., Wang, H., et al., 2009. The
impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of
central nervous system thrombosis and hemorrhage in children with acute lympho-
blastic leukemia receiving asparaginase. Blood 114, 5146–5151.
Al-Ani, F., Bermejo, J.M., Mateos, M.V., Louzada, M., 2016. Thromboprophylaxis in
multiple myeloma patients treated with lenalidomide –a systematic review. Thromb.
Res. 141, 84–90.
Alvarez-Larrán, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V.,
Hernández-Boluda, J.C., et al., 2010. Observation versus antiplatelet therapy as
primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood
116, 1205–1210.
Alvarez-Larrán, A., Pereira, A., Arellano-Rodrigo, E., Hernández-Boluda, J.C., Cervantes,
F., Besses, C., 2013. Cytoreduction plus low-dose aspirin versus cytoreduction alone
as primary prophylaxis of thrombosis in patients with high-risk essential thrombo-
cythaemia: an observational study. Br. J. Haematol. 161, 865–871.
Athale, U.H., Chan, A.K., 2003. Thrombosis in children with acute lymphoblastic leu-
kemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic
leukemia. Thromb. Res. 111, 125–131.
Athale, U.H., Nagel, K., Khan, A.A., Chan, A.K., 2008. Thromboembolism in children with
lymphoma. Thromb. Res. 122, 459–465.
Barbui, T., Carobbio, A., Rambaldi, A., Finazzi, G., 2009. Perspectives on thrombosis in
essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
Blood 114, 759–763.
Barbui, T., Carobbio, A., Cervantes, F., Vannucchi, A.M., Guglielmelli, P., Antonioli, E.,
et al., 2010. Thrombosis in primary myeloﬁbrosis: incidence and risk factors. Blood
115, 778–782.
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M.,
European LeukemiaNet, et al., 2011. Philadelphia-negative classical myeloprolifera-
tive neoplasms: critical concepts and management recommendations from European
Leukemia Net. J. Clin. Oncol. 29, 761–770.
Barbui, T., Finazzi, G., Falanga, A., 2013. Myeloproliferative neoplasms and thrombosis.
Blood 122, 2176–2184.
Barbui, T., 2011. How to manage thrombosis in myeloproliferative neoplasms. Curr.
Opin. Oncol. 23, 654–658.
Bennett, C.L., Angelotta, C., Yarnold, P.R., Evens, A.M., Zonder, J.A., Raisch, D.W., et al.,
2006. Thalidomide- and lenalidomide-associated thromboembolism among patients
with cancer. JAMA 296, 2558–2560.
Bever, K.M., Masha, L.I., Sun, F., Stern, L., Havasi, A., Berk, J.L., et al., 2016. Risk factors
for venous thromboembolism in immunoglobulin light chain amyloidosis.
Haematologica 101, 86–90.
Blom, J.W., Doggen, C.J., Osanto, S., Rosendaal, F.R., 2005. Malignancies, prothrombotic
mutations, and the risk of venous thrombosis. JAMA 293, 715–722.
Breccia, M., Avvisati, G., Latagliata, R., Carmosino, I., Guarini, A., De Propris, M.S., et al.,
2007. Occurrence of thrombotic events in acute promyelocytic leukemia correlates
with consistent immunophenotypic and molecular features. Leukemia 21, 79–83.
Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., United
Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult
Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group, et al.,
2005. Deﬁnition of subtypes of essential thrombocythemia and relation to poly-
cythemia Vera based on JAK2 V617F mutation status: a prospective study. Lancet
366, 1945–1953.
Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., et al.,
2011. Risk factors for arterial and venous thrombosis in WHO-deﬁned essential
thrombocythemia: an international study of 891 patients. Blood 117, 5857–5859.
Carrier, M., Le Gal, A., Tay, J., Wu, C., Lee, A.Y., 2011. Rates of venous thromboembolism
in multiple myeloma patients undergoing immunomodulatory therapy with
Thalidomide and lenalidomide: a systematic review and meta-analysis. J. Thromb.
Haemost. 9, 653–663.
Carrier, M., Khorana, A.A., Zwicker, J.I., Noble, S., Lee, A.Y.Y., on behalf of the sub-
committee on Haemostasis and Malignancy for the SSc of the ISTH, 2013.
Management of challenging cases of patients with cancer-associated thrombosis in-
cluding recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J.
Thromb. Haemost. 11, 1760–1765.
Caruso, V., Iacoviello, L., Di Castelnuovo, A., Storti, S., Mariani, G., de Gaetano, G., et al.,
2006. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-
analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 108,
2216–2222.
Caruso, V., Iacoviello, L., Di Castelnuovo, A., Storti, S., Donati, M.B., 2007. Venous
thrombotic complications in adults undergoing induction treatment for acute lym-
phoblastic leukemia: results from a meta-analysis. J. Thromb. Haemost. 5, 621–623.
Caruso, V., Di Castelnuovo, A., Meschengieser, S., Lazzari, M.A., de Gaetano, G., Storti, S.,
et al., 2010. Thrombotic complications in adult patients with lymphoma: a meta-
analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood
115, 5322–5328.
Castelli, R., Ferrari, B., Cortelezzi, A., Guariglia, A., 2010a. Thromboembolic complica-
tions in malignant haematological disorders. Curr. Vasc. Pharmacol. 8, 482–494.
Castelli, R., Ferrari, B., Cortelezzi, A., Guariglia, A., 2010b. Thromboembolic complica-
tions in malignant haematological disorders. Curr. Vasc. Pharmacol. 8, 482–494.
Christiansen, C.F., Schmidt, M., Lamberg, A.L., Horváth-Puhó, E., Baron, J.A., Jespersen,
B., et al., 2014. Kidney disease and risk of venous thromboembolism: a nationwide
population- based case-control study. J. Thromb. Haemost. 12, 1449–1454.
Condat, B., Pessione, F., Hillaire, S., Denninger, M.H., Guillin, M.C., Poliquin, M., et al.,
2001. Current outcome of portal vein thrombosis in adults: risk and beneﬁt of an-
ticoagulant therapy. Gastroenterology 120, 490–497.
Cortelezzi, A., Moia, M., Falanga, A., Pogliani, E.M., Agnelli, G., Bonizzoni, E., et al.,
2005. Incidence of thrombotic complications in patients with hematological malig-
nancies with central venous catheters: a prospective multicenter study. Br. J.
Haematol. 129, 811–817.
Table 5
Suggested Strategies for Prophylaxis and Treatment of VTE in Hematological Malignancies by Platelets count.
Platelets ≥50,000/μL >20,000/μL e < 50,000/μL ≤20,000/μL
Prophylaxis Therapy Prophylaxis Therapy Prophylaxis Therapy
A. Myeloproliferative Disorders
Acute Myeloid Leukemia and
Myelodysplastic Syndrome
LMWHa LMWHb LMWHa LMWHb Stop LMWH Stop LMWH
Polycythemia Vera and
Essential Thrombocythemia
ASA LMWHb LMWHa LMWHb Stop LMWH Stop LMWH
Myeloﬁbrosis Usually not
recommended with the
exception of selected
high risk conditions
LMWHb Usually not recommended
with the exception of
selected high risk
conditions
LMWHb Not recommended IVC ﬁlter
B. Lymphoproliferative Disorders
Acute Lymphoid Leukemia LMWHa LMWHb LMWHa LMWHb Stop LMWH Stop LMWH
Hodgkin Lymphoma ASAc LMWHb LMWHa LMWHb Stop LMWH Stop LMWH
Non Hodgkin Lymphoma
• Diﬀuse large B cell
Lymphoma
• Follicular Lynphomas• Lymphoplasmacytic
Lymphoma and
Waldenström Disease
• CNS Lymphoma• Other Lymphomas
LMWH as indicated in
ASCO guidelines (87)
LMWH as
indicated in
ASCO guidelines
(87)
Reduce by 50% the
Prophylactic dosage of
LMWH indicated in ASCO
guidelines (85)
Reduce by 50% the
Therapeutic dosage of
LMWH indicated in
ASCO guidelines(85)
Stop LMWH Stop LMWH
Multiple Myeloma ASAc LMWHb LMWHa LMWHb Discontinue LMWH Discontinue
LMWH
Amyloidosis AL Only in selected high risk
conditions
IVC ﬁlter? Not recommended IVC ﬁlter Not recommended IVC ﬁlter
Legend: LMWH (Low Molecular Weight Heparin); ASA (Aspirin); IVC (Intra venous Caval).
a Tnzaparin: 4500 IU daily; Dalteparin: 5000 IU daily; Enoxaparin: 4000 IU daily).
b Tinzaparin: 175 IU/Kg daily up to 6 months; Dalteparin: 200 IU daily for the 1st month, 150 IU daily for the following 5 months; Enoxaparin: 100 IU twice daily).
c ASA (Aspirin: 80–100mg daily).
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